Interestingly 1,25(OH)2D3 increase development of Th2 cells via a direct effect on naive CD4+ cells49 and to induce regulatory T cells.50 Consequently, VDR agonists appear to primarily inhibit pro inflammatory, pathogenic T cells such as Th1 and Th17 cells, and to favor development of Th2 or T regulatory cells.51 The anti-inflammatory, immune regulatory and pro-tolerogenic properties of VDR agonists indicate their important role in the physiological regulation of innate and adaptive immune responses and suggest their development as potential therapies for autoimmune disorders.51, 52. The gene discussed is VDR; the disease is Autoimmunity.